Acquisition of Fukang OTC Pharmacy
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Xenitra Limited has announced the acquisition of Fukang OTC Pharmacy, enhancing its operations in the OTC medicine market in China. The acquisition includes obtaining a pharmaceutical license and various assets necessary for the OTC business. Chairman Anthony Noble expressed excitement about the operationalization of their OTC business and the potential for product expansion in the China market. This announcement has been approved by the board of directors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Xenitra
- OPAL Token & Xen Shop Launch - Next-Gen Digital Commerce
- $30m Danone - Rockcheck Strategic Partnership
- Half Yearly Report and Accounts
- EZZ: EZZ Appoints Aumake in $10m Exclusive Dist Agreement
- $10m Exclusive Dist Agreement with EZZ Life Sciences
Later from Xenitra
- Q3 Sales rise by over 305% to $8.3m
- OPAL token launch of EZZ products sells $100k in first week
- $1.25m Raised to Support Next Phase of Growth
- Product sales of $500k in first month of OPAL token launch
- XEN Appointed as Exclusive Biomiq Skincare China Distributor
Follow Xenitra into a list and get an email when it puts out news.
Follow Xenitra